NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









HAYA Therapeutics

HAYA Therapeutics

Private
LausanneHealthcare & Life Scienceshttps://www.hayatx.com/

Last Round

Series A

May 8, 2025

Total Funding Raised

$91.79M

Company Overview

HAYA Therapeutics is a biotechnology company developing programmable therapeutics targeting regulatory RNAs to reprogram pathological cell states for a broad range of diseases, including cardiovascular and metabolic diseases and cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Application

Keywords

lncRNAlong non-coding RNAdrug discoveryRNA therapeuticsprecision medicineoligonucleotide therapeuticsregulatory genomeRNA medicineAI drug discoveryfunctional genomicsgenomics AIbiotech platformundruggable targetscausal intelligencebiotech R&D

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

HAYA Therapeutics Comps

Public and private peers based on sector, stage, and business model.

HAYA Therapeutics comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

HAYA Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AMay 8, 2025
GrantFeb 12, 2025
SeedFeb 9, 2022
SeedMay 20, 2021
GrantAug 16, 2018
Grant
Feb 2, 2018

Key People

Founding team and executive leadership

Daniel Blessing

Co-Founder, Chief Technology Officer And Board Director

Founding Team

Eric Adam

Chief Operating Officer

Executive Team

HAYA Therapeutics Investors

Notable investors and investment history

HAYA Therapeutics investors
InvestorRounds
LifeLink VenturesSeries A
4see venturesSeed, Series A
+ND CapitalSeries A
Viva BioInnovatorSeed
Humboldt FundSeed
Athos CapitalSeries A
Viva BiotechSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Oct 1, 2025

    Lead program HTX-001 advancing for hypertrophic cardiomyopathy treatment.

  • Oct 1, 2025

    Received the Innosuisse Certificate for Sustainable Growth.

HAYA Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

HAYA Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about HAYA Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersLausanne
Employee Range69
Year Founded2017
Last FundingMay 8, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.